97820-87-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxy-3-oxo-pentanenitrile is used as a synthetic intermediate for the production of various drugs and pharmaceutical compounds. Its unique reactivity and functional properties make it a valuable building block in the synthesis of complex organic molecules.
Used in Agrochemical Industry:
5-Methoxy-3-oxo-pentanenitrile is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its versatile chemical structure allows for the development of new and effective compounds for agricultural applications.
Used in Organic Chemistry Research:
5-Methoxy-3-oxo-pentanenitrile is used as a research compound in the field of organic chemistry. Its unique properties and reactivity make it an interesting subject for studies on chemical reactions and the development of new synthetic methods.
Used in Chemical Engineering:
5-Methoxy-3-oxo-pentanenitrile is used in chemical engineering for the development of new processes and technologies for the synthesis of organic compounds. Its potential applications in various industries make it a valuable compound for the design and optimization of chemical production processes.

Upstream product

• 3852-09-3 methyl 3-methoxypropionate 
• 75-05-8 acetonitrile 

Downstream Products

• 97820-74-1 5-(2-Methoxy-ethyl)-2-methyl-2H-pyrazol-3-ylamine 
• 97821-09-5 3-(2-Methoxy-ethyl)-1,6-dimethyl-4-(3-nitro-phenyl)-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Dihydro pyridine compound, its composition, preparation method and use

Disclosed dihydropyridine compounds are the compounds possessing the following general formula (I) as shown in the specification, wherein R1 is selected from hydrogen, halogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic groups, substituted heterocyclic groups, ester group and amide group; R2 is selected from hydrogen, cyanogroup, alkyl, substituted alky, alkenyl, substituted alkenyl and acyl; or R2 and R3 form a fused ring; R3 is selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R3 and R2 or R4 form a fused ring; R4 is selected from hydrogen, alkyl and substituted alkyl; or R4 and R3 or R5 form a fused ring; R5 is selected form alkyl, substituted alky, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R5 and R4 form a fused ring. The invention also discloses a preparation method of the compounds of the general formula (I), compositions containing the compounds of the general formula (I), and applications of the compositions to medicaments for treating cancers.

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF

This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated